



JAMDA

journal homepage: www.jamda.com

Original Study

Differential Association of Frailty With Cognitive Decline and Sarcopenia in Community-Dwelling Older Adults

Shu Nishiguchi RPT, MSc^{a,b,*}, Minoru Yamada RPT, PhD^c, Naoto Fukutani RPT, MSc^a, Daiki Adachi RPT^a, Yuto Tashiro RPT^a, Takayuki Hotta RPT^a, Saori Morino RPT^a, Hidehiko Shirooka RPT^a, Yuma Nozaki RPT^a, Hinako Hirata RPT^a, Moe Yamaguchi RPT^a, Hidenori Arai MD, PhD^a, Tadao Tsuboyama MD, PhD^a, Tomoki Aoyama MD, PhD^a

^aDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan

^bJapan Society for the Promotion of Science, Tokyo, Japan

^cGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tokyo, Japan

A B S T R A C T

Keywords:

Frailty
cognitive decline
sarcopenia
community-dwelling older adults

Objectives: Frailty in older adults is a serious problem because of various adverse health outcomes in many countries with aging populations, such as Japan. The purpose of this study was to determine whether frailty and pre-frailty are associated with cognitive decline and sarcopenia in community-dwelling older adults.

Design: This is a cross-sectional study.

Setting: Japan.

Participants: The participants were 273 Japanese community-dwelling older women aged 65 years and older.

Measurements: We used the frailty criteria developed by the Cardiovascular Health Study to define physical frailty. We divided the cohort into nonfrail, prefrail, and frail according to frailty scores. Cognitive decline and memory decline were defined by using the Mini-Mental State Examination and Scenery Picture Memory Test, respectively. Sarcopenia was defined according to the diagnostic algorithm recommended by the Asian Working Group for Sarcopenia.

Results: In the multivariate logistic regression analysis by using non-frail participants as the reference, pre-frail elderly individuals were significantly more likely to have sarcopenia than non-frail elderly individuals [odds ratio (OR): 2.77, 95% confidence interval (CI): 1.05–9.26], but not cognitive decline or memory decline. Frail elderly individuals were significantly more likely to have cognitive decline (OR: 5.76, 95% CI: 1.20–27.6), memory decline (OR: 5.53, 95% CI: 1.64–18.7) and sarcopenia (OR: 19.1, 95% CI: 3.73–98.0) than non-frail elderly individuals.

Conclusions: Sarcopenia was associated with pre-frailty and frailty, whereas cognitive decline was associated only with frailty.

© 2014 AMDA – The Society for Post-Acute and Long-Term Care Medicine.

Frailty in older adults is a serious concern in countries with aging populations, such as Japan. In general, frailty is defined as a vulnerable state that places older adults at high risk for adverse health outcomes, such as falls, hospitalization, and mortality.^{1,2} Using the frailty criteria developed by the Cardiovascular Health Study, the overall prevalence of frailty in community-dwelling adults aged 65 or older in the United States has been found to range from 7% to 12% and

was greater in women than in men.¹ In Japanese, the prevalence of frailty in community-dwelling adults aged 65 or older was 11.3%, and it increased with aging.³ Frail older adults are considered to have a substantially increased risk of disability, dependency, and need for long-term care insurance. Therefore, prevention and early detection of frailty is important for addressing age-related health care issues.

The causes of frailty are not clearly defined, but it has been suggested that age-related physical changes are the main causes of frailty.⁴ Sarcopenia, defined as progressive loss of skeletal muscle mass, strength, and physical function, is regarded as a key component of physical frailty.^{5,6} The Interventions on Frailty Working Group assessed various methods for screening, recruiting, evaluating, and

The authors declare no conflicts of interest.

* Address correspondence to Shu Nishiguchi, RPT, MSc, Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

E-mail address: nishiguchi.shu.82s@st.kyoto-u.ac.jp (S. Nishiguchi).

<http://dx.doi.org/10.1016/j.jamda.2014.07.010>

1525-8610/© 2014 AMDA – The Society for Post-Acute and Long-Term Care Medicine.

retaining frail elderly individuals in clinical trials.⁷ They reported that most researchers focused on the following domains when identifying physical frailty: mobility, such as lower-extremity performance and gait abnormalities; muscle weakness; poor exercise tolerance; unstable balance; and factors related to body composition, such as weight loss, malnutrition, and muscle loss.⁷ Age-dependent loss of skeletal muscle mass is a multifactorial process; contributing factors include physical inactivity, malnutrition, oxidative stress, changes in endocrine function, and increases in inflammatory cytokines.⁵ Thus, the domains of frailty overlap with the factors related to sarcopenia, and both frailty and sarcopenia mutually result in adverse health outcomes.^{5,6}

Of note, some definitions of frailty include cognitive function and dementia.^{4,8} Several cross-sectional studies have reported an association between physical frailty and cognitive function.^{1,7,9,10} In addition, longitudinal studies have revealed that a higher level of physical frailty is associated with increased risk of incident Alzheimer's disease (AD)¹¹ and mild cognitive impairment.¹² It has been indicated that frailty is associated with AD pathology¹³ and its biological mechanisms.¹⁴ However, not all dementia patients become frail; therefore, the association between frailty and cognitive impairment warrants further study.

Frailty is associated with sarcopenia and cognitive decline. Furthermore, frailty has been considered to include other aspects, such as psychosocial issues and comorbidities.¹⁵ However, it is unclear whether the associations between frailty and cognitive decline as well as between frailty and sarcopenia are different according to the level of frailty. Therefore, the purpose of this study was to determine whether frailty and prefrailty are associated with cognitive decline and sarcopenia in community-dwelling older adults.

Methods

Participants

Participants for this study were recruited through the local press; 273 Japanese women aged 65 years and older (mean age 73.0 ± 5.4 years) responded. We included community-dwelling older adults who were independent in activities of daily living. Participants were interviewed and excluded if they met any of the following criteria: severe cardiac, pulmonary, or musculoskeletal disorders; severe neurologic disorders, such as Parkinson disease and stroke; and participation in Japan's long-term care service. The following data were collected from each participant: age, height, weight, and number of medications being consumed.

Written informed consent was obtained from each participant in accordance with the guidelines approved by the Kyoto University Graduate School of Medicine and the Declaration of Human Rights, Helsinki, 1975. The study protocol was approved by the ethical committee of the Kyoto University Graduate School of Medicine.

Assessment of Frailty

We measured physical frailty domains determined in a previous study.³ As in that study, we considered the frailty phenotype to be characterized by limitations in the following 5 domains by using frailty criteria developed by the Cardiovascular Health Study¹: slowness, weakness, exhaustion, low activity, and shrinking. To measure slowness, each participant's 10-m normal walking speed (m/s) was calculated, and a slow walk was defined as <1.0 m/s. To measure weakness, low grip strength was established according to a sex-specific cutoff of the average grip strength in each arm (women: <17 kg). Exhaustion was assessed via self-report by using the Geriatric Depression Scale¹⁶ (ie, exhaustion was defined as a negative ["no"] answer to the

question "do you feel full of energy?") We evaluated the role of physical activity by asking the following questions about time spent engaged in sports and exercise: (1) "Do you engage in moderate levels of physical exercise or sports aimed at health?" and (2) "Do you engage in low levels of physical exercise aimed at health?" If a participant answered "no" to both of these questions, then we considered their physical activity to be low. Shrinking was established according to self-reports of weight loss in response to the following question: "In the past 2 years, have you lost more than 5% of your body weight irrespective of intent to lose weight?" If a participant answered "yes" to this question, then we considered them to have shrunk. We calculated the number of affected domains and classified participants as follows: prefrailty = 1 or 2, frailty ≥ 3 .¹

Measurement of Cognitive Function

Participants' cognitive function was measured by using 2 neuropsychological tests: the Mini-Mental State Examination (MMSE)¹⁷ and the Scenery Picture Memory Test (SPMT).¹⁸

Global cognitive function was assessed by using the MMSE, a standard test in cognitive aging research to assess mental status. The MMSE tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall, and language. It has 11 questions and a possible maximum score of 30. We divided the participants into a normal or a cognitive decline group based on a cut-off of 23/24 as the MMSE score.¹⁹

The SPMT is a simple memory test that assesses visual memory combined with verbal responses. This test uses a line drawing of a living room in a house with 23 objects commonly observed in daily life on an A4 piece of paper. The examinee is instructed to look at the picture for 1 minute and remember the items. After this encoding period, participants are distracted by completing a brief digits forward test. Participants are then asked to recall the objects in the picture without a time limitation. The recall usually takes approximately 2 minutes. The number of items recalled is the score for the SPMT. We divided the participants into a normal or memory decline group based on a cut-off of 9/10 as the SPMT score.¹⁸

Definition of Sarcopenia

We defined sarcopenia by using the diagnostic algorithm recommended by the Asian Working Group for Sarcopenia, which assesses the presence of both low muscle function (low physical performance or low muscle strength) and low muscle mass.²⁰ A bioelectrical impedance data acquisition system (Inbody 430; Biospace Co, Ltd, Seoul, Korea) was used to perform bioelectrical impedance analysis.²¹ This system uses electrical current at multiple frequencies (5, 50, 250, 500, and 1000 kHz) to directly measure the amount of extracellular and intracellular water. Participants stood on 2 metallic electrodes and held metallic grip electrodes. Using segmental body composition, appendicular skeletal muscle mass was determined and used for further analysis. Skeletal muscle mass index (SMI) was calculated by dividing muscle mass by height squared in meters (kg/m^2). This index has been used in several epidemiological studies.^{22,23} If a participant had both low muscle function (slow walking speed, ≤ 0.8 m/s; low grip strength for women, ≤ 18 kg) and low SMI (low muscle mass for women, ≤ 5.7 kg/m^2), then they were defined as having sarcopenia.²⁰

Statistical Analysis

Prior to the analysis, we classified participants into the following 3 groups according to their frailty score: nonfrailty, prefrailty, and frailty. Differences in the demographic variables, MMSE, SPMT, and

Download English Version:

<https://daneshyari.com/en/article/6049863>

Download Persian Version:

<https://daneshyari.com/article/6049863>

[Daneshyari.com](https://daneshyari.com)